10-Q: Anixa Biosciences Q2 2026 Financial Results

Anixa Biosciences reports a net loss of $2.5 million for the second quarter of 2026 while continuing clinical development of its oncology pipeline.

Summary

• Reported a net loss of $2.5 million for the three months ended April 30, 2026, compared to a $2.8 million loss in the same period last year.
• Operating expenses for the quarter were $2.6 million, down from $3.0 million in the prior year period.
• Maintained a cash, cash equivalents, and short-term investment balance of $13.7 million as of April 30, 2026.
• Raised approximately $2.87 million in net proceeds through an at-the-market equity offering during the six-month period.
• Clinical trials for the ovarian cancer CAR-T therapy (lira-cel) and breast cancer vaccine continue to progress with no revenue generated to date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral report; the company is executing its clinical development plan as expected, but remains in a cash-burning phase with no near-term revenue prospects.

Positives

• Operating expenses decreased by approximately $356,000 for the quarter compared to the prior year period.
• The company maintains a strong liquidity position with sufficient cash to fund operations for at least the next 12 months.
• Clinical trials for the ovarian cancer CAR-T therapy have shown anecdotal signs of efficacy and extended survival in patients.
• The breast cancer vaccine Phase 1 trial successfully met all primary study endpoints.

Negatives

• The company continues to generate no revenue from its core therapeutics and vaccine programs.
• Accumulated deficit increased to $256.8 million as of April 30, 2026.
• Net loss remains significant at $5.1 million for the six-month period.
• Interest income declined due to lower investment balances and interest rates.

Risks

• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• Future success is entirely dependent on the outcome of clinical trials and regulatory approvals, which are inherently uncertain.
• The company may require significant additional capital to fund future clinical trials and commercialization efforts.
• Reliance on third-party collaborators and research institutions for clinical trial execution.

Future Outlook

The company expects to focus primarily on the development of its therapeutics and vaccine programs over the next several quarters. It aims to eventually license its technologies to large pharmaceutical companies, though it does not expect to generate revenue from these programs in the near term.

Management Comments

• Management believes existing cash and investments are sufficient to fund operations for at least the next twelve months.
• Management views the anecdotal evidence of extended survival in the ovarian cancer CAR-T trial as encouraging.

Industry Context

StockSavvy.ai notes that Anixa Biosciences operates in the high-risk, high-reward biotechnology sector, where companies often rely on equity financing to fund long-term clinical development. The company's strategy of collaborating with research institutions like the Cleveland Clinic and Moffitt Cancer Center is a common capital-preservation model for early-stage biotech firms.

Comparison to Industry Standards

• The company's reliance on external research institutions for clinical trials is consistent with lean biotech development models.
• The lack of revenue is standard for pre-commercial biotechnology companies in the clinical trial phase.
• The use of at-the-market equity offerings is a common practice for small-cap biotech companies to maintain liquidity without the high costs of a traditional underwritten offering.

Legal Proceedings

• The company is not a party to any material pending legal proceedings other than routine patent enforcement matters.

Stakeholder Impact

• Shareholders face ongoing dilution risk from potential future equity offerings.
• Patients may benefit from the continued development of novel oncology therapies.

Next Steps

• Initiate Phase 2 clinical trial for the breast cancer vaccine.
• Continue patient enrollment and dose escalation in the ovarian cancer CAR-T trial.
• Continue research into new vaccine targets for lung, colon, and prostate cancers.

Key Dates

Recommendation

The company is a speculative, pre-revenue biotech firm. While clinical progress is positive, the lack of revenue and reliance on equity financing make it a high-risk hold for investors awaiting further clinical data.

Keywords

Anixa Biosciences, ANIX, Biotechnology, Oncology, CAR-T, Cancer Vaccine, Clinical Trials, 10-Q